More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

AstraZeneca took a step forward in its $39-billion acquisition of Alexion Pharmaceuticals with approval of the deal from the US Federal Trade Commission last month. The deal, which is expected to close in the third quarter 2021, provides...

The Biotechnology Innovation Organization and the Pharmaceutical Research and Manufacturers of America have raised concerns over recently re-introduced legislation in Congress over drug pricing. The bill includes measures for international drug...

New product development is the lifeblood of any industry. Smaller bio/pharmaceutical companies are accounting for an increasingly larger portion of new products as measured by recent new molecular entity approvals. Which companies are making the...

The European Commission took another step to address ways to improve the resilience of the EU's pharmaceutical manufacturing value chain by issuing a revised roadmap for its Pharmaceutical Strategy for Europe. The revised roadmap, which is open to...

Last week (April 14, 2021), the FDA issued final guidance on remote inspections, which the FDA has used in lieu of onsite inspections due to COVID-19 restrictions. The FDA is outlining what to expect in remote inspections, including how to prepare,...

ICROM and PolyCrystalLine SpA announce their strategic and exclusive partnership to provide integrated solutions for chemical development and custom manufacturing of APIs.

Driven by increased biologic-based drug development and industry capacity needs, biomanufacturing is an active area of investment for CDMOs/CMOs with several large-scale expansions recently announced or underway. What CDMOs/CMOs are expanding? DCAT...

The Biden Administration has proposed $6.5 billion in funding to establish a new federal agency within the National Institutes of Health to drive bio/pharmaceutical innovation in areas such as cancer, diabetes, Alzheimer’s disease, and other areas...

Viatris, the new company formed from the combination of Mylan and Upjohn, Pfizer’s off-patent branded and generic established medicines business, is proceeding with a $1-billion restructuring initiative, which includes a rationalization of its...